[30 November 2014] The Society for Neuro-Oncology 2014 Annual Meeting (SNO 2014) was held in Miami, Florida on 13-16 November 2014. Over 1,900 delegates from 43 countries attended the conference, confirming it as the largest and most important neuro-oncology-specific event of the year.
A major highlight of the conference was the presentation by Dr Roger Stupp of the interim results from Novocure’s phase III clinical trial in newly diagnosed GBM (EF-14). The overall survival (OS) data was very positive and has resulted in early termination of the trial due to success. Other highlights included presentations on: Celldex Therapeutics’ immunotherapy treatment, rindopepimut; the use of bevacizumab (Avastin) and lomustine in recurrent GBM; the addition of PCV (procarbazine, CCNU and vincristine) to radiotherapy for the treatment of low grade gliomas; and the genomic characterisation of diffuse low grade gliomas. All of these studies may eventually lead to changes in clinical practice.
The IBTA was recognised with a SNO Public Service Award presented in absentia to the former chair, Denis Strangman (Australia). Our full report from the conference can be downloaded here.